![]() analyst Filippo Falorni, who has a neutral rating on Kenvue. ![]() The debate centers around management’s ability to run the company better as a standalone firm, wrote Citigroup Inc. But delivering growth will be the driving factor in the stock’s success going forward. The bulk of Kenvue’s initial gains are credited to its valuation catching up to the likes of Procter & Gamble Co., analysts agreed. has erased more than one-quarter of its value after a first day pop. shares have jumped more than 30% since a strong debut while biopharma Acelyrin Inc. Solar power tracking company NEXTracker Inc. The drop is emblematic of the mixed reception for stocks that have gone public this year. Shares have slumped about 9% from a peak three weeks ago after rallying 22% in its first session on the back of a split from the health-care giant, which came with a $4.4 billion initial public offering on May 3. In addition, J&J retaining a 90% stake in Kenvue after the spinoff will remain an overhang until those shares are sold into the market, he wrote. While strong brand equity paired with a high market share and the potential for strategic deals may justify a higher valuation, there are concerns around growth, said Deutsche Bank’s Steve Powers, who launched coverage with a neutral rating. The lackluster response centers on whether the company can deliver strong results with its iconic brands like Tylenol and Listerine facing softer consumer spending habits after a rush in demand during the pandemic. Russia’s Dam-Busting Is Another War CrimeĮight of the 11 analysts that cover the consumer health company advise clients against buying shares, an anomaly on the Street, which is in the business of selling stock by focusing on what’s seen as an appropriate valuation. SEC’s Coinbase Lawsuit Heralds Deepening US Crypto Crackdown George Santos Loses Bid to Shield the People Who Guaranteed His $500,000 Bail Ukraine Dam Blast Blamed on Russia Tips War Into New Phase PGA Tour Bows to Saudi Rival in Shock Combination With LIV Golf But just a few weeks after the stock’s initial surge, Wall Street is urging investors to avoid the shares. looked like a winner following its May spinoff from Johnson & Johnson in the year’s biggest IPO.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |